Antitrust probes singe Indian pharma

28 November 2022

Several Indian pharmaceutical companies are facing the dual challenges of antitrust investigations and being sued by multinational pharmaceutical companies. There has been an increase in probes by the US regulator for possible market failures, such as failure to follow good manufacturing practices and deviations from the regulatory path, in the past few months, with multiple cases scorching the growth plans of Indian drug companies, reports The Pharma Letter’s India correspondent.

A lawsuit recently named Dr Reddy's Laboratories (BSE: 500124) and several other generic companies as defendants for lymphoma generic of Celgene’s Revlimid (lenalidomide).

The complaint filed in New Jersey on November 18 against Dr Reddy's, Celgene, Bristol Myers Squibb (NYSE: BMS; which subsequently acquired Celgene), and several other generic companies alleges that the companies improperly restrained competition for the generics and maintained a shared monopoly. The complaint also alleges that the companies sought to delay generic entry until 2026.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK